Rock Springs Capital Management is a fund manager in Baltimore with $5.88 bn assets under management.
Company profile
Website
Employees
Incorporated
Location
Fiscal year end
Industry
SEC CIK
IRS number
800944416
SEC advisor number
801-78511
FINRA CRD number
168648
AUM ?
$5.88 bn
(as of 8 Nov 22)
Accounts
6
(as of 8 Nov 22)
Employees
21
(9 investment advisory or research)
Address
Rock Springs Capital Management
650 SOUTH EXETER STREET
SUITE 1070
BALTIMORE
MD 21202
650 SOUTH EXETER STREET
SUITE 1070
BALTIMORE
MD 21202
Office hours
Monday - Friday, 8:00 AM - 6:00 PM
Phone
4102200129
Ownership
Owner | Title | From | %Ownership |
---|---|---|---|
Rock Springs Capital LLC | General Partner | 03/2013 | < 5% |
Bussard, Gordon, Margraf ("Mark") | Member/limited Partner | 03/2013 | 25-50% |
Mcphail, Graham, Morgan | Member/limited Partner | 03/2013 | 25-50% |
Jenner, Kris, Harlan | Member/limited Partner | 03/2013 | 25-50% |
Bussard, Gordon, Margraf ("Mark") | Member | 03/2013 | 25-50% |
Mcphail, Graham, Morgan | Member | 03/2013 | 25-50% |
Jenner, Kris, Harlan | Member | 03/2013 | 25-50% |
Etoh, Nnamdi, C | Chief Financial Officer | 01/2021 | < 5% |
O'connor, Aidan, Hugh | Chief Compliance Officer and General Counsel | 10/2022 | < 5% |
Ownership
Fund structure | AUM | Fund type |
---|---|---|
Rock Springs Capital | $5.88 bn | |
Four Pines Master Fund LP | $167.40 mm | Hedge Fund |
Four Pines Onshore Fund LP | ||
Four Pines Offshore Fund LP | ||
Rock Springs Capital Master Fund LP | $4.28 bn | Hedge Fund |
Rock Springs Capital Fund LP | ||
Rock Springs Capital Offshore Fund LP |
Latest filings (excl ownership)
No filings
Latest ownership filings
13F-HR
Quarterly holdings report by institutional manager
15 May 24
SC 13G
Travere Therapeutics, Inc.
1 May 24
SC 13G/A
Xilio Therapeutics, Inc.
5 Apr 24
SC 13G
Xilio Therapeutics, Inc.
14 Feb 24
SC 13G/A
Tempest Therapeutics, Inc.
14 Feb 24
SC 13G/A
SPRUCE BIOSCIENCES, INC.
14 Feb 24
SC 13G/A
Mereo BioPharma Group plc
14 Feb 24
SC 13G/A
Mereo BioPharma Group plc
14 Feb 24
SC 13G/A
Inozyme Pharma, Inc.
14 Feb 24
SC 13G/A
Immunocore Holdings plc
14 Feb 24